Hemab Announces Q3 26 Results, Initiates Phase 3 & Doses HMB-003
Hemab Therapeutics reported Q3 2026 financial results and initiated a pivotal Phase 3 trial for Glanzmann thrombasthenia, expanding its clinical-stage coagulation portfolio.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed